SB 838 – California
Introduced: 2022 Status: Enacted
Health care: insulin manufacturing. Existing law requires the California Health and Human Services Agency to enter into partnerships to increase patient access to affordable drugs, including partnerships to produce or distribute generic prescription drugs and …
SB 852 – California
Introduced: 2020 Status: Enacted Year Enacted: 2020
A first-in-the-nation law that will put the state government in direct competition with private drug manufacturers. By January, California must forge partnerships with one or more drug companies to make or distribute a broad range …
SB 874 (see companion bill AB 1046) – Wisconsin
Introduced: 2018 Status: Inactive / Dead
This bills requires that no manufacturer or wholesale distributor may sell or offer to sell an essential off-patent or generic drug at a price that results in price gouging. Under the bill, price gouging means …
SB 879 – Oklahoma
Introduced: 2023 Status: In Process
provides that pharmacy benefits manager (PBM) contracts shall not prohibit from or penalize for a pharmacy or pharmacist disclosing to an individual information regarding the existence and clinical efficacy of a generic equivalent nor shall …
SB 88 – Alabama
Introduced: 2019 Status: Inactive / Dead
Relating to prescriptions; to amend Section 34-23-8, Code of Alabama 1975, to provide that an electronic prescription from a practitioner specify whether a generic product may be dispensed.
SF 0075 – Wyoming
Introduced: 2018 Status: Enacted
PRESCRIPTION DRUGS AUTHORIZATION OF INTERCHANGEABLE BIOLOGICAL PRODUCTS: Would permit a pharmacist to substitute an interchangeable biological for the prescribed original biologic product or substitute the generic equivalent of a prescribed pharmaceutical, unless the prescriber has …
SF 1265 (see companion bill HF 1183) – Minnesota
Introduced: 2021 Status: Inactive / Dead
Drug distributors prescription drugs pricing prohibition; board of pharmacy, commissioner of human services, and health plan companies attorney general drug price increases notification; attorney general action authorization; civil penalties authorization.
SF 168 (see companion bill HF 17) – Minnesota
Introduced: 2023 Status: In Process
S.F. 168 prohibits a manufacturer from imposing or causing to be imposed an excessive price increase on the sale of any generic or off-patent drug sold, dispensed, or delivered to any Minnesota consumer. The bill …
SF 184 – Minnesota
Introduced: 2021 Status: Inactive / Dead
Affordable drugs act access preservation
SF 2841 (see companion bill HF 3131) – Minnesota
Introduced: 2018 Status: Inactive / Dead
DRUG MANUFACTURER OR WHOLESALE DISTRIBUTOR PROHIBITED FROM PRICE GOUGING: A manufacturer or wholesale drug distributor may not engage in price gouging in the sale of an essential off-patent or generic drug. A price increase is considered …
SF 292 (see companion bill HF 204, replaced by SF 489) – Iowa
Introduced: 2019 Status: Inactive / Dead
A bill for an act relating to continuity of care and nonmedical switching by health carriers, health benefit plans, and utilization review organizations, and including applicability provisions. (See SF 489.)
SF 307 – Iowa
Introduced: 2023 Status: In Process
An act relating to step therapy protocols and interchangeable biosimilars
SF 346 (see companion bill HF 1904) – Minnesota
Introduced: 2021 Status: Inactive / Dead
Drug formulary and prior authorization provisions modified, preferred drug list requirements modified, and Formulary Committee reorganizing report required.
SF 3768 (see companion bill HF 4266) – Minnesota
Introduced: 2022 Status: Inactive / Dead
Requiring prescription drug benefit transparency and disclsoure. A health plan company that provides prescription drug benefit coverage and uses a formulary must make its formulary and related benefit information available by electronic means and, upon …
SF 489 – Iowa
Introduced: 2019 Status: Inactive / Dead
A bill for an act relating to continuity of care for covered persons with epilepsy, and nonmedical switching by health carriers, health benefit plans, and utilization review organizations, and including applicability provisions. (Formerly SF 292.)
SF 990 (see companion bill HF 1516) – Minnesota
Introduced: 2021 Status: Inactive / Dead
Pharmacy and provider choice allowed relating to biological product prescription and dispensation, and report required. (a) A pharmacy benefit manager or health carrier must not require or demonstrate a preference for a pharmacy or health …